Irofulven
- Generic Name
- Irofulven
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C15H18O3
- CAS Number
- 158440-71-2
- Unique Ingredient Identifier
- 6B799IH05A
- Background
A novel anti-cancer compound synthesized by scientists at the University of California, San Diego more than a decade ago from toxins of the poisonous jack-o-lantern mushroom, has been granted “fast track” status by the U.S. Food and Drug Administration (FDA) after demonstrating promise against one of the most deadly cancers.
MGI-114 (Irofulven) is currently being developed by MGI PHARMA, Inc., an emerging oncology-focused pharmaceutical company based in Minneapolis. Phase III clinical trials involving the drug have been underway since early 2001 at sites in the U.S. and Europe.
- Indication
Investigated for use/treatment in brain cancer, breast cancer, endometrial cancer, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, pediatric indications, prostate cancer, and sarcoma.
- Associated Conditions
- -
- Associated Therapies
- -
Irofulven in Treating Patients With Stage IV Melanoma
- Conditions
- Melanoma (Skin)
- First Posted Date
- 2004-06-21
- Last Posted Date
- 2013-05-30
- Lead Sponsor
- University of Colorado, Denver
- Registration Number
- NCT00005968
- Locations
- 🇺🇸
John Wayne Cancer Institute, Santa Monica, California, United States
🇺🇸Ellis Fischel Cancer Center - Columbia, Columbia, Missouri, United States
🇺🇸University of Colorado Cancer Center, Denver, Colorado, United States
6-Hydroxymethylacylfulvene in Treating Patients With Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Blastic Phase Chronic Myelogenous Leukemia
- First Posted Date
- 2004-06-03
- Last Posted Date
- 2013-02-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 25
- Registration Number
- NCT00003997
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Irofulven in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer
- Conditions
- Fallopian Tube CancerPrimary Peritoneal Cavity CancerOvarian Cancer
- First Posted Date
- 2004-04-13
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00019552
- Locations
- 🇺🇸
Medicine Branch, Bethesda, Maryland, United States
Irofulven in Treating Children With Recurrent or Refractory Solid Tumors
- Conditions
- Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2004-02-09
- Last Posted Date
- 2013-02-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 12
- Registration Number
- NCT00003370
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Children's Hospital of Columbus, Columbus, Ohio, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer
- Conditions
- Primary Peritoneal Cavity CancerRecurrent Ovarian Epithelial Cancer
- Interventions
- First Posted Date
- 2003-01-28
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 61
- Registration Number
- NCT00053365
- Locations
- 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
Irofulven in Treating Patients With Metastatic Breast Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 32
- Registration Number
- NCT00003796
- Locations
- 🇺🇸
University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.